United States Platelet Rich Plasma Market Report by Product Type (Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich Plasma (LPRP), Leukocyte- and Platelet-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (P-PRF)), Origin (Autologous PRP, Homologous PRP, Allogeneic PRP), Application (Orthopedics, Cosmetic Surgery and Dermatology, Neurosurgery, General Surgery, Cardiothoracic Surgery, Urology, Ophthalmology, and Others), End User (Hospitals and Clinics, Research Institutes, and Others), and Region 2025-2033

United States Platelet Rich Plasma Market Report by Product Type (Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich Plasma (LPRP), Leukocyte- and Platelet-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (P-PRF)), Origin (Autologous PRP, Homologous PRP, Allogeneic PRP), Application (Orthopedics, Cosmetic Surgery and Dermatology, Neurosurgery, General Surgery, Cardiothoracic Surgery, Urology, Ophthalmology, and Others), End User (Hospitals and Clinics, Research Institutes, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A3291

Market Overview:

The United States platelet rich plasma market size reached USD 271.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 581.2 Million by 2033, exhibiting a growth rate (CAGR) of 8.38% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 271.7 Million
Market Forecast in 2033
USD 581.2 Million
Market Growth Rate (2025-2033) 8.38%


Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).

The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country. Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market report, along with forecasts at the country level from 2025-2033. Our report has categorized the market based on product type, origin, application, and end user.

Breakup by Product Type:

United States Platelet Rich Plasma Market

  • Pure Platelet-Rich Plasma (P-PRP)
  • Leukocyte- and Platelet-Rich Plasma (LPRP)
  • Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • Pure Platelet-Rich Fibrin (P-PRF)
     

Breakup by Origin:

  • Autologous PRP
  • Homologous PRP
  • Allogeneic PRP
     

Breakup by Application:

  • Orthopedics
  • Cosmetic Surgery and Dermatology
  • Neurosurgery
  • General Surgery
  • Cardiothoracic Surgery
  • Urology
  • Ophthalmology
  • Others
     

Breakup by End User:

  • Hospitals and Clinics
  • Research Institutes
  • Others
     

Breakup by Region:

United States Platelet Rich Plasma Market By Region

  • Northeast
  • Midwest
  • South
  • West
     

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Million USD
Segment Coverage Product Type, Origin, Application, End User, Region
Region Covered Northeast, Midwest, South, West
Companies Covered Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The United States platelet rich plasma market was valued at USD 271.7 Million in 2024.

We expect the United States platelet rich plasma market to exhibit a CAGR of 8.38% during 2025-2033.

The rising consumer awareness towards numerous benefits associated with platelet rich plasma treatment, such as preventing inflammation, encouraging new cartilage formulation, inducing natural lubrication fluid production, etc., is primarily driving the United States platelet rich plasma market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cosmetic, orthopedics, and neuro surgical procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the United States market for platelet rich plasma.

Based on the product type, the United States platelet rich plasma market has been divided into pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF). Among these, pure platelet-rich plasma (P-PRP) currently exhibits a clear dominance in the market.

Based on the origin, the United States platelet rich plasma market can be categorized into autologous PRP, homologous PRP, and allogeneic PRP. Currently, autologous PRP accounts for the majority of the total market share.

Based on the application, the United States platelet rich plasma market has been segregated into orthopedics, cosmetic surgery and dermatology, neurosurgery, general surgery, cardiothoracic surgery, urology, ophthalmology, and others. Among these, orthopedics currently exhibit a clear dominance in the market.

Based on the end user, the United States platelet rich plasma market can be bifurcated into hospitals and clinics, research institutes, and others. Currently, hospitals and clinics hold the largest market share.

On a regional level, the market has been classified into Northeast, Midwest, South, and West, where West currently dominates the United States platelet rich plasma market.

Some of the major players in the United States platelet rich plasma market include Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc., and Zimmer Biomet Holdings Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
United States Platelet Rich Plasma Market Report by Product Type (Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich Plasma (LPRP), Leukocyte- and Platelet-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (P-PRF)), Origin (Autologous PRP, Homologous PRP, Allogeneic PRP), Application (Orthopedics, Cosmetic Surgery and Dermatology, Neurosurgery, General Surgery, Cardiothoracic Surgery, Urology, Ophthalmology, and Others), End User (Hospitals and Clinics, Research Institutes, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials